TD Private Client Wealth LLC Sells 8,311 Shares of Charles River Laboratories International, Inc. $CRL

TD Private Client Wealth LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 97.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 221 shares of the medical research company’s stock after selling 8,311 shares during the period. TD Private Client Wealth LLC’s holdings in Charles River Laboratories International were worth $34,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC grew its stake in Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 144 shares during the period. Brooklyn Investment Group lifted its holdings in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at approximately $31,000. Parallel Advisors LLC increased its stake in Charles River Laboratories International by 83.7% during the 1st quarter. Parallel Advisors LLC now owns 474 shares of the medical research company’s stock worth $71,000 after purchasing an additional 216 shares in the last quarter. Finally, Family Legacy Financial Solutions LLC acquired a new stake in Charles River Laboratories International during the 2nd quarter worth approximately $71,000. 98.91% of the stock is currently owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of CRL opened at $156.61 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company’s fifty day simple moving average is $159.46 and its 200 day simple moving average is $147.31. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a market cap of $7.71 billion, a price-to-earnings ratio of -117.75, a PEG ratio of 3.93 and a beta of 1.47.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the firm posted $2.80 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Wall Street Zen raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Monday. Barclays lifted their price target on Charles River Laboratories International from $155.00 to $165.00 and gave the company an “equal weight” rating in a research note on Thursday, August 7th. Finally, Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their price objective for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $177.07.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).